Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived betax000D
cells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasingx000D
capability. The project represents a new collaboration between two leading Canadian technology developers:x000D
Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprintingx000D
technology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developedx000D
for the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab willx000D
provide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyondx000D
(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structuresx000D
using Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized forx000D
cell viability, maturation, and insulin production in response to nutrients, both in vitro and following implantx000D
into mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing thex000D
immunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunityx000D
for students in cutting edge biomedical engineering at the interface of academia and industry, and could lead tox000D
substantial investments in follow-up research and development.